Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDMO Avid Bioservices	$12.50 +0.1%	$12.50	$6.61 ▼ $12.51	$799.18M	1.39	1.43 million shs	3.07 million shs
CMRX Chimerix	$8.54	$8.54	$0.75 ▼ $8.55	$801.09M	-0.17	2.71 million shs	N/A
MNPR Monopar Therapeutics	$33.60 -4.0%	$36.75	$1.72 ▼ $54.30	$214.09M	0.99	360,287 shs	567,062 shs
ORIC Oric Pharmaceuticals	$10.31 -1.8%	$7.16	$3.90 ▼ $14.67	$894.85M	1.49	802,765 shs	3.00 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDMO Avid Bioservices	0.00%	0.00%	0.00%	0.00%	+78.25%
CMRX Chimerix	0.00%	0.00%	0.00%	+0.47%	+867.16%
MNPR Monopar Therapeutics	-4.03%	+2.25%	+3.51%	-16.69%	+801.41%
ORIC Oric Pharmaceuticals	-1.81%	+10.74%	+72.70%	+67.92%	+55.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDMO Avid Bioservices	0.8941 of 5 stars	1.0	0.0	4.5	1.5	1.7	0.6
CMRX Chimerix	0.6562 of 5 stars	1.0	0.0	4.1	0.6	1.7	0.6
MNPR Monopar Therapeutics	3.0003 of 5 stars	3.4	5.0	0.0	2.1	2.5	0.0
ORIC Oric Pharmaceuticals	4.2469 of 5 stars	3.5	1.0	4.3	2.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDMO Avid Bioservices	2.00	Hold	$12.25	-1.96% Downside
CMRX Chimerix	2.00	Hold	$8.53	-0.08% Downside
MNPR Monopar Therapeutics	2.80	Moderate Buy	$56.50	68.15% Upside
ORIC Oric Pharmaceuticals	3.00	Buy	$19.17	85.90% Upside

Current Analyst Ratings Breakdown

Latest MNPR, CMRX, CDMO, and ORIC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/29/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/6/2025	ORIC Oric Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $12.00
5/6/2025	ORIC Oric Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/5/2025	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
4/2/2025	MNPR Monopar Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/1/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDMO Avid Bioservices	$139.91M	5.71	$0.15 per share	80.92	$3.02 per share	4.14
CMRX Chimerix	$212K	3,778.71	N/A	N/A	$2.17 per share	3.94
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDMO Avid Bioservices	-$140.75M	-$2.39	N/A	N/A	N/A	-101.07%	-33.18%	-8.45%	6/30/2025 (Estimated)
CMRX Chimerix	-$82.10M	-$0.99	N/A	N/A	N/A	N/A	-50.78%	-44.94%	8/11/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	8/8/2025 (Estimated)
ORIC Oric Pharmaceuticals	-$127.85M	-$1.87	N/A	N/A	N/A	N/A	-51.14%	-46.29%	8/11/2025 (Estimated)

Latest MNPR, CMRX, CDMO, and ORIC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/5/2025	Q1 2025	ORIC Oric Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A
3/31/2025	Q4 2024	MNPR Monopar Therapeutics	-$0.36	-$2.23	-$1.87	-$2.23	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDMO Avid Bioservices	N/A	N/A	N/A	N/A	N/A
CMRX Chimerix	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDMO Avid Bioservices	3.58	1.30	0.92
CMRX Chimerix	N/A	6.33	6.33
MNPR Monopar Therapeutics	N/A	36.91	36.91
ORIC Oric Pharmaceuticals	N/A	12.00	12.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDMO Avid Bioservices	97.16%
CMRX Chimerix	45.42%
MNPR Monopar Therapeutics	1.83%
ORIC Oric Pharmaceuticals	95.05%

Insider Ownership

Company	Insider Ownership
CDMO Avid Bioservices	3.05%
CMRX Chimerix	13.10%
MNPR Monopar Therapeutics	20.50%
ORIC Oric Pharmaceuticals	6.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDMO Avid Bioservices	320	63.96 million	62.01 million	Optionable
CMRX Chimerix	90	93.80 million	78.15 million	Optionable
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable
ORIC Oric Pharmaceuticals	80	85.22 million	79.41 million	Optionable

MNPR, CMRX, CDMO, and ORIC Headlines

Recent News About These Companies

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up After Insider Buying Activity

June 26 at 2:15 AM | americanbankingnews.com

Oric Pharmaceuticals Shows Market Leadership With Jump To 93 RS Rating

June 25 at 1:33 PM | msn.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $10,340.00 in Stock

June 25 at 6:12 AM | insidertrades.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 1,034 Shares

June 24, 2025 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $340,893.00 in Stock

June 24, 2025 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Insider Buying Activity

June 24, 2025 | marketbeat.com

Angie You Purchases 1,403 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock

June 24, 2025 | insidertrades.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You Acquires 26,597 Shares

June 23, 2025 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You Acquires 1,403 Shares

June 23, 2025 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.2% - Here's What Happened

June 23, 2025 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Receives Outperform Rating from Wedbush

June 23, 2025 | marketbeat.com

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

June 19, 2025 | zacks.com

Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?

June 19, 2025 | zacks.com

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 3.4% - Should You Sell?

June 16, 2025 | marketbeat.com

What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?

June 13, 2025 | zacks.com

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down on Insider Selling

June 12, 2025 | marketbeat.com

Millennium Management LLC Trims Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

June 12, 2025 | marketbeat.com

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 2,976 Shares

June 11, 2025 | marketbeat.com

Oric Pharmaceuticals files to sell 19.23M shares of common stock by selling shareholders

June 11, 2025 | msn.com

Cantor Fitzgerald Weighs in on ORIC FY2026 Earnings

June 11, 2025 | marketbeat.com

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from Analysts

June 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR, CMRX, CDMO, and ORIC Company Descriptions

Avid Bioservices NASDAQ:CDMO

$12.50 +0.02 (+0.12%)

Closing price 02/5/2025

Extended Trading

$12.50 0.00 (0.00%)

As of 02/5/2025 04:23 PM Eastern

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.

Chimerix NASDAQ:CMRX

$8.54 0.00 (0.00%)

As of 04/21/2025

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Monopar Therapeutics NASDAQ:MNPR

$33.60 -1.41 (-4.03%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$33.59 -0.01 (-0.03%)

As of 06/27/2025 05:50 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Oric Pharmaceuticals NASDAQ:ORIC

$10.31 -0.19 (-1.81%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$10.40 +0.09 (+0.87%)

As of 06/27/2025 07:56 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time